Fifteen studies with 3,414 patients were included in the review. Seven studies were controlled (n=2,438) and eight were uncontrolled (n=976).
Cancer reoccurrence.
After approximately 7 years' follow-up, cancer reoccurrence occurred in 10% (95% CI: 8.4, 11.6) of HT patients (based on all studies).
When the controlled studies were pooled, patients on HT had a decreased risk of cancer reoccurrence in comparison with the control groups (OR 0.5, 95% CI: 0.2, 0.7). No statistically significant heterogeneity was found.
Cancer mortality.
After approximately 7 years' follow-up, cancer mortality occurred in 2.6% (95% CI: 1.8, 3.7) of HT patients (based on all studies).
When the controlled studies were pooled, patients on HT had a decreased risk of cancer mortality in comparison with the control groups (OR 0.3, 95% CI: 0.0, 0.6). No statistically significant heterogeneity was found.
All-cause mortality.
After approximately 7 years' follow-up, all-cause mortality was 4.5% (95% CI: 3.4, 5.8) of HT patients (based on all studies).
Statistically significant heterogeneity was found for the meta-analysis using data from controlled studies.